TY - JOUR T1 - Assessing the impact of coordinated COVID-19 exit strategies across Europe JF - medRxiv DO - 10.1101/2020.06.16.20132688 SP - 2020.06.16.20132688 AU - N.W. Ruktanonchai AU - J.R. Floyd AU - S. Lai AU - C.W. Ruktanonchai AU - A. Sadilek AU - P. Rente-Lourenco AU - X. Ben AU - A. Carioli AU - J. Gwinn AU - J.E. Steele AU - O. Prosper AU - A. Schneider AU - A. Oplinger AU - P. Eastham AU - A.J. Tatem Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/19/2020.06.16.20132688.abstract N2 - As rates of new COVID-19 cases decline across Europe due to non-pharmaceutical interventions such as social distancing policies and lockdown measures, countries require guidance on how to ease restrictions while minimizing the risk of resurgent outbreaks. Here, we use mobility and case data to quantify how coordinated exit strategies could delay continental resurgence and limit community transmission of COVID-19. We find that a resurgent continental epidemic could occur as many as 5 weeks earlier when well-connected countries with stringent existing interventions end their interventions prematurely. Further, we found that appropriate coordination can greatly improve the likelihood of eliminating community transmission throughout Europe. In particular, synchronizing intermittent lockdowns across Europe meant half as many lockdown periods were required to end community transmission continent-wide.One Sentence Summary EU coordination in easing restrictions is key to preventing resurgent COVID-19 outbreaks and stopping community transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the grants from the Vodafone Institute; the Bill & Melinda Gates Foundation (OPP1134076); the European Union Horizon 2020 (MOOD 874850). AJT is supported by funding from the Bill & Melinda Gates Foundation (INV-002697, OPP1106427, OPP1032350, OPP1134076, OPP1094793), the Clinton Health Access Initiative, the UK Department for International Development (DFID) and the Wellcome Trust (106866/Z/15/Z, 204613/Z/16/Z). NR is supported by funding from the Bill & Melinda Gates Foundation (OPP1170969). OP is supported by the National Science Foundation (1816075).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ERGO 48113All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesERGO ID 48113 ER -